Literature DB >> 19434887

Pharmacological profile of progestins.

Regine Sitruk-Ware1.   

Abstract

The synthetic progestins used so far for contraception and menopausal hormone therapy are derived either from testosterone (19-nortestosterone derivatives) or from progesterone (17-OH progesterone derivatives and 19-norprogesterone derivatives). Among the 19-nortestosterone derivatives, the estrane group include norethisterone (NET) and its metabolites, and the gonane group include levonorgestrel (LNG) and its derivatives. The later, including desogestrel (DSG) and its derivative etonogestrel, gestodene (GES) and norgestimate (norelgestromin), have been referred to as third-generation progestins. Several new progestins have been synthesized in the last decade and may be considered as a fourth-generation of progestins. Dienogest is referred to as a hybrid progestin being derived from the estrane group with a 17alpha-cyanomethyl group, and drospirenone derives from spirolactone. These two progestins have no androgenic effect but a partial antiandrogenic effect. The later exerts anti-mineralocorticoid effects. This property leads to a decreased salt and water retention and a lowering in blood pressure in users of pills containing this progestin. The 19-norprogesterone derivatives appear more specifically progestational and do not possess any androgenic, estrogenic or glucocorticoid activity. They are referred to as "pure" progestational molecules as they bind almost exclusively to the progesterone receptor (PR) and do not interfere with the other steroid receptor. This category includes, trimegestone, nomegestrol acetate and Nestorone is not active orally but proved to be a potent anti-ovulatory agent when given in implants, vaginal rings or percutaneous gel. Non-androgenic progestins would appear neutral on metabolic factors and on the vessels and would have the advantage of avoiding acnea. Progestins with antiandrogenic properties may also be used for the treatment of women with preexisting androgen related conditions. The progestins available for therapy exhibit profound differences according to their structure or metabolites and it is inappropriate to consider the various effects of the old and new molecules as class-effects.

Entities:  

Year:  2008        PMID: 19434887     DOI: 10.1016/j.maturitas.2008.11.011

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  24 in total

Review 1.  Combined hormonal contraceptives: prescribing patterns, compliance, and benefits versus risks.

Authors:  Jan Brynhildsen
Journal:  Ther Adv Drug Saf       Date:  2014-10

2.  MPA: medroxy-progesterone acetate contributes to much poor advice for women.

Authors:  Cynthia L Bethea
Journal:  Endocrinology       Date:  2011-02       Impact factor: 4.736

Review 3.  Long-acting injectable hormonal dosage forms for contraception.

Authors:  Linfeng Wu; Dileep R Janagam; Timothy D Mandrell; James R Johnson; Tao L Lowe
Journal:  Pharm Res       Date:  2015-04-22       Impact factor: 4.200

4.  Simultaneous assay of segesterone acetate (Nestorone®), estradiol, progesterone, and estrone in human serum by LC-MS/MS.

Authors:  David W Erikson; Steven W Blue; Kristopher M Fecteau; Alison B Edelman; Jeffrey T Jensen; Diana L Blithe
Journal:  Contraception       Date:  2020-08-21       Impact factor: 3.375

5.  Short-term effects of low-dose estrogen/drospirenone vs low-dose estrogen/dydrogesterone on glycemic fluctuations in postmenopausal women with metabolic syndrome.

Authors:  Maria Rosaria Rizzo; Stefania Leo; Pasquale De Franciscis; Nicola Colacurci; Giuseppe Paolisso
Journal:  Age (Dordr)       Date:  2013-07-07

6.  Progesterone and Nestorone facilitate axon remyelination: a role for progesterone receptors.

Authors:  Rashad Hussain; Martine El-Etr; Ouardia Gaci; Jennifer Rakotomamonjy; Wendy B Macklin; Narender Kumar; Regine Sitruk-Ware; Michael Schumacher; Abdel M Ghoumari
Journal:  Endocrinology       Date:  2011-08-09       Impact factor: 4.736

7.  Bleeding profile associated with 1-year use of the segesterone acetate/ethinyl estradiol contraceptive vaginal system: pooled analysis from Phase 3 trials.

Authors:  Carolina Sales Vieira; Ian S Fraser; Marlena G Plagianos; Anne E Burke; Carolyn L Westhoff; Jeffrey Jensen; Vivian Brache; Luis Bahamondes; Ruth Merkatz; Regine Sitruk-Ware; Diana L Blithe
Journal:  Contraception       Date:  2019-08-06       Impact factor: 3.375

Review 8.  Metabolic effects of contraceptive steroids.

Authors:  Regine Sitruk-Ware; Anita Nath
Journal:  Rev Endocr Metab Disord       Date:  2011-06       Impact factor: 6.514

9.  Association of Oral Contraceptives With Drug-Induced QT Interval Prolongation in Healthy Nonmenopausal Women.

Authors:  Joe-Elie Salem; Pauline Dureau; Anne Bachelot; Marine Germain; Pascal Voiriot; Bruno Lebourgeois; David-Alexandre Trégouët; Jean-Sébastien Hulot; Christian Funck-Brentano
Journal:  JAMA Cardiol       Date:  2018-09-01       Impact factor: 14.676

10.  A new strategy for selective targeting of progesterone receptor with passive antagonists.

Authors:  Junaid A Khan; Abdellatif Tikad; Michel Fay; Abdallah Hamze; Jérôme Fagart; Nathalie Chabbert-Buffet; Geri Meduri; Larbi Amazit; Jean-Daniel Brion; Mouad Alami; Marc Lombès; Hugues Loosfelt; Marie-Edith Rafestin-Oblin
Journal:  Mol Endocrinol       Date:  2013-04-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.